Sylvain Thépot

Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

Thomas Prébet, Steven D. Gore, Benjamin Esterni et al. · Journal of Clinical Oncology · 2011 · 480 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

Raphaël Itzykson, Sylvain Thépot, Bruno Quesnel et al. · Blood · 2010 · 386 citations · Full text

Medicine, Oncology, Pharmacology +10

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)

Sylvain Thépot, Raphaël Itzykson, Valérie Seegers et al. · Blood · 2010 · 156 citations

Medicine, Hematology, Oncology +17

Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup

Thomas Prébet, Nicolas Boissel, S. Reutenauer et al. · Journal of Clinical Oncology · 2009 · 134 citations · Full text

Medicine, Geriatric Medicine, Oncology +12

Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study

David P. Steensma, Pierre Fenaux, Koen Van Eygen et al. · Journal of Clinical Oncology · 2020 · 125 citations · Full text

Medicine, Hematology, Pharmacology +13